Publication:
Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control

dc.contributor.authorMasip, Jenifer
dc.contributor.authorRallón, Norma
dc.contributor.authorYeregui, Elena
dc.contributor.authorOlona, Montserrat
dc.contributor.authorResino, Salvador
dc.contributor.authorBenito, José Miguel
dc.contributor.authorViladés, Consuelo
dc.contributor.authorGarcía-Pardo, Graciano
dc.contributor.authorAlcamí, José
dc.contributor.authorRuiz-Mateos, Ezequiel
dc.contributor.authorGómez-Bertomeu, Frederic
dc.contributor.authorVargas, Montserrat
dc.contributor.authorNavarro, Marta
dc.contributor.authorOteo, José A
dc.contributor.authorPineda, Juan A
dc.contributor.authorMartí, Anna
dc.contributor.authorAlba, Verónica
dc.contributor.authorVidal, Francesc
dc.contributor.authorPeraire, Joaquin
dc.contributor.authorRull, Anna
dc.contributor.authorECRIS integrated in the Spanish AIDS Research Network
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderRovira i Virgili University (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderConsejo Superior de Investigaciones Científicas (España)
dc.contributor.funderUnión Europea. Fondo Social Europeo (ESF/FSE)
dc.contributor.funderAgència de Gestió d´Ajuts Universitaris i de Recerca (AGAUR)
dc.contributor.funderGilead Sciences (Spain)
dc.date.accessioned2022-08-05T11:49:47Z
dc.date.available2022-08-05T11:49:47Z
dc.date.issued2022-04-20
dc.description.abstractLong-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by the Fondo de Investigación Sanitaria [PI13/0796, PI16/00503, PI16/0684, PI18/1532, PI19/00004, PI19/01127, PI19/01337 PI16/001769, PI19/00973, and PI20/00326]-ISCIII-FEDER (co-funded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/”Investing in your future”); Programa de Suport als Grups de Recerca AGAUR (2017SGR948); Gilead Fellowship Program GLD14/293; The SPANISH AIDS Research Network [RD16/0002/0001, RD16/0002/0002, RD16/0025/0006, RD16/0025/0013, and RD16/0025/0020]-ISCIII-FEDER (Spain); and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00015, CB21/13/00020, and CB21/13/00044], Madrid, Spain. JM is supported by the Universitat Rovira I Virgili under grant agreement “2019PMF-PIPF-18,” through the call “Martí Franquès Research Fellowship Programme.” NR is a Miguel Servet researcher from the ISCIII [CPII19/00025]. EY is supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “FI20/0011800” through the program “Contratos Predoctorales de Formación en Investigación en Salud.” ER-M was supported by the Spanish National Research Council (CSIC). FV is supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII and by “Premi a la Trajectòria Investigadora als Hospitals de l’ICS 2018.” AR is supported by IISPV through the project “2019/IISPV/05” (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019,” and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146” through the Miguel Servet Program.es_ES
dc.format.page822272es_ES
dc.format.volume13es_ES
dc.identifier.citationFront Immunol. 2022 Apr 20;13:822272.es_ES
dc.identifier.doi10.3389/fimmu.2022.822272es_ES
dc.identifier.e-issn1664-3224es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.identifier.pubmedID35514981es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14870
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0013/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0020/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0002/0001es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0002/0002es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI13/0796es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16/00503es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16/0684es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI18/1532es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/00004es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/01127es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/01337es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16/001769es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/00973es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20/00326es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CPII19/00025es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/FI20/0011800es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/INT20/00031es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP19/00146es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00015es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00020es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00044es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2022.822272es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIV infectiones_ES
dc.subjectKreb's cyclees_ES
dc.subjectElite controllers (ECs)es_ES
dc.subjectLipidomicses_ES
dc.subjectLong-termes_ES
dc.subjectMass spectrometryes_ES
dc.subjectMetabolomicses_ES
dc.subjectVirales_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHIV-1es_ES
dc.subject.meshFollow-Up Studieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshKetoglutaric Acidses_ES
dc.subject.meshLipidses_ES
dc.titleElevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Controles_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublicationf236c6af-7ac3-49fe-8a6a-818b321c6130
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication811243fc-9fda-46b1-b312-9259d8c570f6
relation.isFunderOfPublication36ca2ebf-c6c3-4f53-8618-500af224a277
relation.isFunderOfPublicationaf365449-d1bb-4678-af42-7483b561cd83
relation.isFunderOfPublicatione30731f7-32c2-43af-b658-fe28964bc958
relation.isFunderOfPublication.latestForDiscoveryefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
ElevatedαKetoglutaricAcid_2022.pdf
Size:
2.75 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal
Loading...
Thumbnail Image
Name:
ElevatedαKetoglutaricAcidSupplementeryMaterial_2022.pdf
Size:
514.5 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information